protocolSection identificationModule nctId: NCT06326268, orgStudyIdInfo id: 2023-019, secondaryIdInfos id: 2023-A02133-42, type: OTHER, domain: ID-RCB Number, briefTitle: Interest of Light Therapy in Hematology - The PHOTO-TREAT Study, acronym: PHOTO-TREAT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-17, primaryCompletionDateStruct date: 2025-09-17, completionDateStruct date: 2025-09-17, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Institut de cancérologie Strasbourg Europe, class: OTHER, descriptionModule briefSummary: Chemo-induced mucositis is a common complication in patients treated for hematologic malignancies. They can manifest itself as a simple local irritation with erythema and inflammation but can also progress to erosions and ulcerations of the entire oral mucosa and are also responsible for an increased risk of infection in these immunocompromised patients.The only therapies currently offered are local care and intravenous analgesics. Studies in pediatric hematology show the effectiveness of prevention and low-dose laser treatment in chemo-induced mucositis, both in terms of reducing the number of mucositis developed but also in terms of reducing the grade of mucositis. This currently results in a recommendation for the use of photobiomodulation by international bodies such as ESMO (European Society for Medical Oncology)., conditionsModule conditions: Leukemia, Myeloid, Acute, conditions: Lymphoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Phototherapy system CareMin650TM, outcomesModule primaryOutcomes measure: Evaluate the impact of Photobiomodulation (PBM) therapy in the management of chemo-induced mucositis in terms of prevalence of mucositis, secondaryOutcomes measure: Evaluate the impact of PBM in the management of chemo-induced mucositis in terms of reduction in analgesic consumption., secondaryOutcomes measure: Evaluate the impact of PBM in terms of infection by bacterial translocation risk reduction., secondaryOutcomes measure: Evaluate the impact of PBM in terms of reduction of the use of artificial feeding., secondaryOutcomes measure: Evaluate the impact of PBM in terms of reduction of the length of hospital stay., secondaryOutcomes measure: Evaluate the impact of PBM in terms of reduction of the number of transfusions., secondaryOutcomes measure: Evaluate the impact of PBM in terms of pain reduction, secondaryOutcomes measure: Evaluate the impact of PBM on patient's satisfaction regarding pain management during hospital stay, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institut de cancérologie Strasbourg Europe, status: RECRUITING, city: Strasbourg, zip: 67033, country: France, contacts role: CONTACT, phone: (0)3 68 33 95 23, phoneExt: +33, email: promotion-rc@icans.eu, contacts name: Anne ZILLIOX, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 48.58392, lon: 7.74553, hasResults: False